You are here: Industry Insights > Norgine

News List

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe. PRNewswire
January 27, 2025
Norgine collaborates with X4. X4's MAA for mavorixafor treating WHIM syndrome is under EMA evaluation, and Norgine aims to bring it to Europe, Aus & NZ.
Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma PRNewswire
January 07, 2025
Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB).
Norgine B.V. and US WorldMeds enter into exclusive licensing agreement to commercialise DFMO (eflornithine) in Europe, Commonwealth of Independent States, Australia and New Zealand prnasia
July 23, 2021
NORGINE B.V. today announced an exclusive licensing agreement by which Norgine will register and commercialise difluoromethylornithine, DFMO (eflornithine) in Europe, Commonwealth of Independent States, Australia and New Zealand.
Norgine launches Shield’s Feraccru in the UK pharmatimes
December 07, 2018
Norgine has launched Feraccru across the UK to treat patients with iron deficiency anaemia, having picked up rights to sell the drug from Shield Therapeutics earlier this year.
Norgine buys rights to sell Shield’s iron deficiency therapy pharmatimes
September 20, 2018
Norgine has signed a deal with Shield Therapeutics allowing it to commercialise iron deficiency therapy Feraccru in Europe, Australia and New Zealand.
Norgine Buys Merus Labs for $342M contractpharma
May 12, 2017
European specialist pharmaceutical company Norgine has acquired Merus Labs International for $342 million.
Norgine Presents New Post-hoc Data Analyses Highlighting the Efficacy of PLENVU® for Bowel Cleansing en-cphi.cn
May 08, 2017
Norgine B.V. today presented new post-hoc analyses from the phase III DAYB and MORA studies that demonstrate the high-quality cleansing efficacy of PLENVU®.